CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 25 enrolled
Drug / intervention
adalimumabbiological
Likely dose
Adalimumab 40 mg subcutaneously every other weekAI-extracted
Key inclusion· 3
  • ✓Prior participation in adalimumab study
  • ✓Body weight less than 100 kg
  • ✓Willingness to continue study drug administration
Key exclusion· 10
  • ✕Advanced or poorly controlled diabetes
  • ✕Any poorly controlled medical condition
  • ✕Intra-articular, intramuscular or IV corticosteroid administration during prior study
  • ✕Joint surgery during prior study

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00235833
NCT00235833Phase 2Completed
CompareCT.gov

Long-term Continuously Repeated Dose Study of Adalimumab (D2E7) in Patients With Rheumatoid Arthritis

Abbott·interventional·Posted Oct 12, 2005·Updated Apr 11, 2011

In Brief

A Phase 2 clinical trial evaluating adalimumab for Rheumatoid Arthritis. Completed, enrolled 25 participants across 7 sites.

Detailed Summary

The purpose of the study is to assess the long-term safety, tolerability, and efficacy of repeated administration of adalimumab in adult Japanese subjects with rheumatoid arthritis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesJapan
CollaboratorsAbbott Japan Co.,Ltd, Eisai Co., Ltd.

Timeline

Phase 2CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 12, 2005
Enrollment StartJun 1, 2003
Primary CompletionOct 1, 2004
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 20.7 years ago

Interventions

adalimumabbiological

40 mg every other week (eow), subcutaneous (sc)